Patents by Inventor Jonathan R. Lai

Jonathan R. Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
    Patent number: 10377815
    Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: August 13, 2019
    Assignee: Albert Einstein College of Medicine
    Inventors: Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
  • FILOVIRUS ANTIBODY
    Publication number: 20190185547
    Abstract: The present invention addresses a need for antibodies useful for filovirus infections.
    Type: Application
    Filed: September 18, 2018
    Publication date: June 20, 2019
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCEL OF THE UNIVERSITY OF TORONTO, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
  • SYNTHETIC ANTIBODIES TO BAX AND USES THEREOF
    Publication number: 20190161537
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Application
    Filed: January 30, 2019
    Publication date: May 30, 2019
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • Synthetic antibodies to BAX and uses thereof
    Patent number: 10294294
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: May 21, 2019
    Assignees: Albert Einstein College of Medicine, The Governing Council of the University of Toronto
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • ENGINEERED PD-1 VARIANTS
    Publication number: 20190127439
    Abstract: Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Jonathan R. Lai, Steven Almo, Nina Liu, Julia Frei
  • DENGUE VIRUS GLYCOPROTEIN E DIII VARIANTS AND USES THEREOF
    Publication number: 20180360946
    Abstract: Specific Dengue virus glycoprotein subunit E DIII variants and their uses in preventing and treating Dengue virus infection are disclosed.
    Type: Application
    Filed: February 13, 2017
    Publication date: December 20, 2018
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Jonathan R. Lai, Margaret C. Kielian, Julia C. Frei
  • Therapy for filovirus infection
    Patent number: 10081669
    Abstract: The present invention addresses a need for improved treatments for Filovirus infections.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: September 25, 2018
    Assignees: Albert Einstein College of Medicine, Inc., The Governing Council of the University of Toronto, The United States of America as Represented by the Secretary of the Army
    Inventors: Jonathan R. Lai, Jayne F. Koelhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Jr., Samantha Zak
  • SYNTHETIC ANTIBODIES TO BAX AND USES THEREOF
    Publication number: 20180251532
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Application
    Filed: August 25, 2016
    Publication date: September 6, 2018
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • ANTIBODY THERAPEUTICS AGAINST FILOVIRUS INFECTIONS AND USES THEREOF
    Publication number: 20180141999
    Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
    Type: Application
    Filed: May 4, 2016
    Publication date: May 24, 2018
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
    Inventors: Kartik Chandran, Anna Z. Wec, Elisabeth K. Nyakatura, Jonathan R. Lai
  • THERAPY FOR FILOVIRUS INFECTION
    Publication number: 20170204166
    Abstract: The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.
    Type: Application
    Filed: August 6, 2015
    Publication date: July 20, 2017
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
  • MULTI-SPECIFIC ANTIBODIES FOR CROSS-NEUTRALIZATION OF MULTIPLE FILOVIRUS GLYCOPROTEINS
    Publication number: 20170182163
    Abstract: Methods for treating and for preventing Filovirus infections are disclosed, as well as compositions therefor.
    Type: Application
    Filed: January 12, 2017
    Publication date: June 29, 2017
    Applicant: Albert Einstein College of Medicine, Inc.
    Inventors: Jonathan R. Lai, Julia Frei, Elisabeth Nyakatura
  • THERAPY FOR FILOVIRUS INFECTION
    Publication number: 20170088606
    Abstract: The present invention addresses a need for improved treatments for Filovirus infections.
    Type: Application
    Filed: May 23, 2016
    Publication date: March 30, 2017
    Applicant: Albert Einstein College of Medicine, Inc.
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, JR., Samantha Zak
  • Constructs and methods to identify antibodies that target glycans
    Patent number: 9360483
    Abstract: Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: June 7, 2016
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Jonathan R. Lai, Alex Stewart
  • Therapy for filovirus infection
    Patent number: 9346875
    Abstract: The present invention addresses a need for improved treatments for filovirus infections.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: May 24, 2016
    Assignees: Albert Einstein College of Medicine, Inc., The Governing Council of the University of Toronto, The United States of America as Represented by the Secretary of the Army
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Jr., Samantha Zak
  • THERAPY FOR FILOVIRUS INFECTION
    Publication number: 20140356354
    Abstract: The present invention addresses a need for improved treatments for filovirus infections.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, University of Toronto, Government of the United States
    Inventors: Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, JR., Samantha Zak
  • CONSTRUCTS AND METHODS TO IDENTIFY ANTIBODIES THAT TARGET GLYCANS
    Publication number: 20130281317
    Abstract: Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans.
    Type: Application
    Filed: November 23, 2011
    Publication date: October 24, 2013
    Applicant: Allbert Einstein College of Medicine of Yeshiva University
    Inventors: Jonathan R. Lai, Alex Stewart
  • Methods of Producing Modified Assembly Lines and Related Compositions
    Publication number: 20100048422
    Abstract: The present invention provides a method producing a modified assembly line, such as those that produce non-ribosomal peptides and polyketides. The modified assembly lines of the invention can be used to produce novel compounds with therapeutic activities. The invention also provides organisms containing modified assembly lines and libraries of modified assembly lines.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 25, 2010
    Inventors: Christopher T. Walsh, Michael A. Fischbach, Jonathan R. Lai, David R. Liu, Zhe Zhou
  • Polypeptides containing ?-amino acids
    Patent number: 6958384
    Abstract: Disclosed are polypeptide compounds containing at least one residue comprising a cyclically-constrained ?-amino acid residue. The compounds have the formula where A is a hydrogen, hydroxy, amino- or carboxy-protecting group, Y is a single bond or a prolyl-containing linking group, and X and Y are ?-amino acid residues, provided that one of X or Y is a conformationally-restrained ?-amino acid residue, and “a,” “c,” and “d” are positive integers. The compounds find use as non-enzymatically degradable probes to mimic protein behavior in solution.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: October 25, 2005
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Samuel H. Gellman, Matthew G. Woll, Jonathan R. Lai, Justin Murray
  • Polypeptides containing gamma-amino acids
    Publication number: 20030211999
    Abstract: Disclosed are polypeptide compounds containing at least one residue comprising a cyclically-constrained &ggr;-amino acid residue.
    Type: Application
    Filed: March 14, 2003
    Publication date: November 13, 2003
    Inventors: Samuel H. Gellman, Matthew G. Woll, Jonathan R. Lai, Justin Murray